-
VERAXA and Quadira Enter ADC Development Partnership
contractpharma
June 16, 2021
VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), an ADC engineering and functional antibody screening company, has entered into a partnership with Quadira Biosciences AG of Zug, Switzerland, to develop a suite of novel ADCs for the treatment of ...
-
WuXi XDC and LegoChem Ink ADC Agreement
contractpharma
June 15, 2021
WuXi XDC, a global CDMO providing end-to-end bioconjugates services, and LegoChem Biosciences (LCB), signed a Memorandum of Understanding (MOU) for a partnership in development and manufacturing of antibody-drug conjugates (ADCs).
-
VERAXA Biotech and Quadira Biosciences Enter Partnership on ADC Development
b3cnewswire
June 15, 2021
VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), announced today that it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland, to jointly develop a suite of novel ADCs for the treatment of oncological conditions.
-
Iksuda Therapeutics raises $47m to progress ADC pipeline
pharmatimes
June 08, 2021
Newcastle, UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets.
-
Pandemic inevitably slows pharma M&A activity but appetite for deals remains
cphi-online
June 07, 2021
The initial outbreak of the COVID-19 pandemic delayed merger and acquisitions in the pharma sector, but evidence points to an uptick in activity because the rationale for sealing deals hasn’t changed
-
Avid Bioservices to Manufacture Zynlonta for ADC Therapeutics
contractpharma
May 26, 2021
Avid Bioservices Inc., a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing development and manufacturing services to biotechnology and pharmaceutical companies, will serve as ...
-
Zydus launches Ujvira (trastuzumab emtansine) for breast cancer treatment
expresspharma
May 25, 2021
Zydus Cadila launched Trastuzumab Emtansine, an antibody-drug conjugate (ADC) biosimilar and a drug for treating both early and advanced HER2 positive breast cancer, under the brand name ‘Ujvira’.
-
Sterling Pharma Appoints Stewart Mitchell as New Site Head
contractpharma
May 25, 2021
Sterling Pharma Solutions, a global CDMO, has appointed Stewart Mitchell as site head of its new antibody-drug conjugate (ADC) facility in Deeside, UK. Dr. Mitchell will lead the Deeside facility, and report to Kevin Cook ...
-
GeneQuantum Raises Hundreds of Millions RMB in Series C Funding
prnasia
May 19, 2021
GeneQuantum Healthcare (Suzhou) Co., Ltd. announced the completion of Series C fund raising of several hundreds of millions RMB.
-
Novasep Expands HPAPI Manufacturing Capacity
contractpharma
May 14, 2021
Novasep has expanded its highly potent active pharmaceutical ingredients (HPAPIs) manufacturing capabilities on its Le Mans, France site.